» Articles » PMID: 35693785

An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy

Overview
Journal Front Immunol
Date 2022 Jun 13
PMID 35693785
Authors
Affiliations
Soon will be listed here.
Abstract

Since the re-classification of membranoproliferative glomerulonephritis the new disease entity C3 glomerulopathy is diagnosed if C3 deposition is clearly dominant over immunoglobulins in immunohistochemistry or immunofluorescence. Although this new definition is more orientated at the pathophysiology as mediated by activity of the alternative complement pathway C3 glomerulopathy remains a heterogenous group of disorders. Genetic or autoimmune causes are associated in several but not in all patients with this disease. However, prognosis is poorly predictable, and clinicians cannot directly identify patients that might benefit from therapy. Moreover, therapy may range from supportive care alone, unspecific immune suppression, plasma treatment, or plasma exchange to complement inhibition. The current biopsy based diagnostic approaches sometimes combined with complement profiling are not sufficient to guide clinicians neither (i) whether to treat an individual patient, nor (ii) to choose the best therapy. With this perspective, we propose an interdisciplinary diagnostic approach, including detailed analysis of the kidney biopsy for morphological alterations and immunohistochemical staining, for genetic analyses of complement genes, complement activation patterning in plasma, and furthermore for applying novel approaches for convertase typing and complement profiling directly in renal tissue. Such a combined diagnostic approach was used here for a 42-year-old female patient with a novel mutation in the Factor H gene, C3 glomerulopathy and signs of chronic endothelial damage. We present here an approach that might in future help to guide therapy of renal diseases with relevant complement activation, especially since diverse new anti-complement agents are under clinical investigation.

Citing Articles

Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.

Tschongov T, Konwar S, Busch A, Sievert C, Hartmann A, Noris M Front Immunol. 2024; 15:1383123.

PMID: 38799460 PMC: 11117068. DOI: 10.3389/fimmu.2024.1383123.


Complement Activation in Nephrotic Glomerular Diseases.

Nell D, Wolf R, Podgorny P, Kuschnereit T, Kuschnereit R, Dabers T Biomedicines. 2024; 12(2).

PMID: 38398059 PMC: 10886869. DOI: 10.3390/biomedicines12020455.

References
1.
Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C . Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol. 2017; 29(1):283-294. PMC: 5748907. DOI: 10.1681/ASN.2017030258. View

2.
Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M . Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88(5):1153-60. DOI: 10.1038/ki.2015.227. View

3.
Zipfel P, Wiech T, Stea E, Skerka C . Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol. 2020; 31(2):241-256. PMC: 7003313. DOI: 10.1681/ASN.2019050515. View

4.
le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M . Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2014; 65(3):484-9. DOI: 10.1053/j.ajkd.2014.09.025. View

5.
Zipfel P, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S . The role of complement in C3 glomerulopathy. Mol Immunol. 2015; 67(1):21-30. DOI: 10.1016/j.molimm.2015.03.012. View